Alzheimer’s disease treatment research is being pushed beyond amyloid-only thinking by two very different leads: a copper-transport approach reported in preclinical work and a psilocybin case report in advanced dementia. The Frontiers case report on psilocybin in advanced Alzheimer’s disease is important because it asks whether lost function may sometimes be hidden by network dysfunction rather than erased by cell death. It is interesting because it sits beside a broader debate about why decades of amyloid-focused work have not delivered the expected clinical payoff.
For decades, much Alzheimer’s research has centered on amyloid-beta, a protein fragment that can build up in the brain. The amyloid hypothesis says that this buildup helps trigger the disease process. That idea is still influential, but the treatment record is weak. A Hacker News discussion of copper transport and amyloid skepticism quoted Derek Lowe’s Science blog saying that anti-amyloid therapies “truly, truly do not appear to be the answer” after many failures. The same discussion also noted that amyloid-beta buildup is the predominant theory, not a proven treatment path.
Anti-amyloid antibodies are lab-made immune proteins designed to bind amyloid-beta and help remove it. They represent a direct version of the amyloid strategy. A Derek Lowe’s Science blog critique of anti-amyloid antibodies is relevant because it frames the central frustration: a target can look central to the disease and still be a poor drug target. The Alzheimer’s field is therefore being pushed to test other mechanisms instead of treating amyloid clearance as the only serious path.
Copper is an essential mineral used by many brain enzymes. Copper transport refers to moving copper into, out of, or within cells and tissues. The idea is not simply “more copper” or “less copper.” It is that misplaced or poorly handled copper may disturb proteins, stress cells, and worsen toxic protein buildup. A Hacker News thread summarizing the copper-transport lead described a Monash report as showing that a copper transport drug restored memory and cleared toxic Alzheimer’s proteins.
That is a very different approach from an antibody that hunts amyloid-beta. It may aim at the chemistry around toxic proteins rather than at amyloid itself. The available excerpt also included a caution that the result may be “great news” only if one is a mouse. That caution matters because many Alzheimer’s treatments have worked in animals and failed in people. Another comment said the compound had already undergone safety evaluations for other diseases, which could help human trials start faster. That still would not prove benefit in Alzheimer’s disease.
The Monash University article on a copper transport drug for Alzheimer’s proteins is the original destination for the copper lead. The provided page content for the Monash article only showed a JavaScript and cookies prompt. For that reason, the copper section should be treated as an early lead from the discussion excerpt, not as a settled clinical result. The useful research question remains clear. Can changing copper handling safely clear toxic proteins and improve cognition in humans?
Psilocybin is a psychedelic compound found in some mushrooms. It acts mainly through serotonin 5-HT2A receptors, which are a type of serotonin receptor involved in brain signaling. Human studies show that psilocybin can temporarily change large-scale brain network activity, meaning communication patterns among many brain areas. Preclinical studies also suggest that psychedelics may promote neural plasticity, meaning the brain’s ability to change connections and signaling patterns.
The Frontiers case report on high-dose psilocybin-containing mushrooms in advanced Alzheimer’s disease describes an octogenarian Japanese-American woman with about 10 years of Alzheimer’s disease. For the previous 5 years, she had severe hypofunction, meaning very low activity and responsiveness. She also had mostly monosyllabic speech, bladder incontinence, impaired walking, swallowing difficulty, and dependence in daily activities. She received 5 grams of Enigma strain psilocybin-containing mushrooms. The acute phase included autonomic activation, meaning changes in automatic body functions such as sweating and temperature. It also included clinically suspected hyperthermia, meaning possible high body temperature. It included profuse sweating and a prolonged deep sleep-like state. About 19 hours later, she began spontaneous autobiographical speech, meaning speech about her own life.
Over the following days and weeks, the report described improvements in bladder control, walking, dressing, emotional responsiveness, social interaction, contextual memory, and conversation. One month later, she still had some functional improvement, including sustained urinary continence. A second supervised session used 3 grams of psilocybin-containing mushrooms. The report says this second session was associated with more verbal expression, facial expressivity, humor, autobiographical imagery, and walking agility. The authors emphasize that the findings do not imply disease reversal.
The case is intriguing because advanced Alzheimer’s disease is usually treated as irreversible functional decline. It suggests that some residual function may persist even when it is not easily accessible. It also suggests that network disruption may hide abilities that are not completely destroyed. But the evidence is very limited. The report is a single case. It had no control group. It lacked formal biomarker confirmation, advanced brain scans, standard cognitive tests, and sleep monitoring. The authors say causality cannot be established and spontaneous fluctuations cannot be fully excluded. No severe persistent adverse effects were observed during follow-up, but the acute phase still included concerning symptoms.
The shift away from amyloid-only research does not mean amyloid is irrelevant. It means the field needs more than one explanation and more than one treatment strategy. Copper transport is closer to a disease-modifying hypothesis if it truly changes the underlying disease process. Psilocybin is closer to a network-function hypothesis if it temporarily restores access to residual abilities. Those are different goals, and they should be tested with different trial designs.
A serious research agenda should separate three questions. Does a treatment change the underlying disease process? Does it improve symptoms or function without changing pathology? Does it do so safely enough for frail older adults? For copper transport, researchers need human safety data, dose finding, biological marker evidence, and cognitive outcomes. For psilocybin, researchers need controlled trials, careful monitoring, dose standards, caregiver outcomes, and measures of brain network function.
The main lesson is not that copper or psilocybin will replace amyloid research. The main lesson is that persistence without results becomes dogma. Alzheimer’s disease is too complex for a single-pathway mindset. The next useful step is disciplined testing, not hype.
Anti-amyloid antibodies have not delivered the broad success once expected. Copper transport offers an early and biologically different lead. Psilocybin offers a surprising but very weak clinical signal in one advanced case. None of this is a cure. None of this should encourage self-treatment. The most important change is methodological. Researchers should keep amyloid in the conversation, but stop letting it occupy the whole room.
Grumpy's commentary: After thirty-five years of amyloid fan fiction, even copper and mushrooms look like plot twists.
Bubbles's commentary: New pathways, careful trials, and maybe a little hope with a lab coat on! 🧠✨🍄
Koan's commentary: The lost room was never empty, but the key may only fit once.
Generated at 2026-06-15 18:16:03 from Hacker News with poolside/laguna-xs.2-20260421:free and nex-agi/nex-n2-pro:free
Licensed under Creative Commons Zero (CC0 1.0 Universal)